Progress in clinical fibrinolysis

被引：23
作者：
Emeis, JJ
Verheijen, JH
Ronday, HK
deMaat, MPM
Brakman, P
机构：
来源：
FIBRINOLYSIS & PROTEOLYSIS | 1997年 / 11卷 / 02期
关键词：
D O I：
10.1016/S0268-9499(97)80098-7
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
[No abstract available]
引用
收藏
页码：67 / 84
页数：18
相关论文
共 304 条
[1]  
ACHBAROU A, 1994, CANCER RES, V54, P2372
[2]  
ANDERSON GI, 1995, J BONE MINER RES S1, V10, pS284
[3]  
BACHMAN F, 1995, FIBRINOLYSIS DIS, V1, P79
[4]   TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[5]  
BASHKOV GV, 1993, BLOOD COAGUL FIBRIN, V4, P993
[6]  
BAVENHOLM P, 1995, THROMB HAEMOSTASIS, V73, P568
[7]  
BEER JH, 1994, THROMB HAEMOSTASIS, V71, P622
[8]   NEW VARIANT OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR (TPA) WITH ENHANCED EFFICACY AND LOWER INCIDENCE OF BLEEDING COMPARED WITH RECOMBINANT HUMAN TPA [J].
BENEDICT, CR ;
REFINO, CJ ;
KEYT, BA ;
PAKALA, R ;
PAONI, NF ;
THOMAS, GR ;
BENNETT, WF .
CIRCULATION, 1995, 92 (10) :3032-3040
[9]   ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME [J].
BERGSTEIN, JM ;
RILEY, M ;
BANG, NU .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :755-759
[10]  
BIANCHI E, 1994, CANCER RES, V54, P861
12345678910